
Loading, please wait...

Loading, please wait...

A phase 2b study evaluated the efficacy & safety of Guselkumab, in patients with moderately to severely active ulcerative colitis (UC). Subjects were randomized to receive intravenous Guselkumab 200 or 400 mg or placebo at weeks 0/4/8. Guselkumab 200 mg or 400 mg showed significant improvement in the clinical status of patients compared to placebo at week 12. Guselkumab IV infusion is safe & effective in severely active UC patients.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A phase 2b study evaluated the efficacy & safety of Guselkumab, in patients with moderately to severely active ulcerative colitis (UC). Subjects were randomized to receive intravenous Guselkumab 200 or 400 mg or placebo at weeks 0/4/8. Guselkumab 200 mg or 400 mg showed significant improvement in the clinical status of patients compared to placebo at week 12. Guselkumab IV infusion is safe & effective in severely active UC patients.
3 months ago

Explore vital recurrent stroke predictors in lacunar stroke patients managed with intensive blood pressure lowering. This analysis examines trial findings from SPS3 to uncover residual vascular risks, metabolic factors, and targeted secondary prevention strategies for high-risk neurological patients.
Today

A comprehensive scoping review synthesises evidence linking prenatal maternal mental health to long-term offspring neurodevelopment, evaluating neuroendocrine, inflammatory, and epigenetic pathways while highlighting clinical screening and future research priorities.
Today

The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today

Mitochondria-targeted nanoparticles self-assembled from EGCG and L-glutamic acid effectively restore mitochondrial homeostasis, suppress synovial inflammation, and attenuate chondrocyte senescence in osteoarthritis, offering a promising disease-modifying nanotherapy.
Today

India is advancing preventive healthcare by integrating genomics, artificial intelligence, and quantum technologies. With the SANGAM programme sequencing one million Indian genomes, clinicians can unlock personalized therapies, detect cardiometabolic risks early, and curb the burden of diabetes and heart disease.
Today